Seres Therapeutics Inc. (CH:MCRB)
NASDAQ:MCRB
MCRB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Liquidity And Cost ReductionThe one-time $25M milestone payment from Nestlé plus a lease amendment cutting roughly $33.9M of aggregate lease payments materially improves near-term liquidity and lowers fixed costs. These structural moves extend operating runway, reduce reliance on immediate capital raises, and permanently lower ongoing facility cash demands.
Clinical Pipeline ProgressHaving SER-155 at Phase 2 readiness and imminent investigator-sponsored data represents durable clinical de-risking potential. Progress in the live biotherapeutic pipeline supports long-term value creation if trials validate efficacy, and positions the company to attract partners or non-dilutive funding tied to meaningful clinical milestones.
Partnership-driven Non-dilutive FundingA business model that leverages collaborations and milestone-based deals provides structural access to non-dilutive capital and commercialization channels. Such partnerships can finance R&D, share development risk, and enable commercialization options without immediate equity dilution, helping sustain operations through clinical stages.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow near -$42M TTM signals persistent cash consumption that will require continued external financing or further cost cuts. Over months this increases funding risk, constrains strategic optionality, and forces management to prioritize near-term liquidity over longer-term R&D investments unless burn is structurally reduced.
Elevated LeverageA roughly 3x debt-to-equity posture reduces financial flexibility and raises refinancing and covenant risk, especially for a clinical-stage biotech with volatile cash flows. High leverage can increase interest and fixed obligations, limit ability to fund trials internally, and make the company more vulnerable during capital market stress.
Deep Operating Losses And Tiny Revenue BaseVery low revenues against substantial operating losses (EBIT ~ -$87.6M) reflect an immature commercial position and an expense structure not yet supported by scale. Over the medium term this requires successful clinical outcomes or repeat partner financings to justify continued investment and avoid dilutive financings that could erode equity value.
Seres Therapeutics News
MCRB FAQ
What was Seres Therapeutics Inc.’s price range in the past 12 months?
Currently, no data Available
What is Seres Therapeutics Inc.’s market cap?
Seres Therapeutics Inc.’s market cap is CHF51.65M.
When is Seres Therapeutics Inc.’s upcoming earnings report date?
Seres Therapeutics Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 45 days.
How were Seres Therapeutics Inc.’s earnings last quarter?
Seres Therapeutics Inc. released its earnings results on May 05, 2026. The company reported -$1.634 earnings per share for the quarter, missing the consensus estimate of -$1.477 by -$0.157.
Is Seres Therapeutics Inc. overvalued?
According to Wall Street analysts Seres Therapeutics Inc.’s price is currently Undervalued.
Does Seres Therapeutics Inc. pay dividends?
Seres Therapeutics Inc. does not currently pay dividends.
What is Seres Therapeutics Inc.’s EPS estimate?
Seres Therapeutics Inc.’s EPS estimate is -1.81.
How many shares outstanding does Seres Therapeutics Inc. have?
Currently, no data Available
What happened to Seres Therapeutics Inc.’s price movement after its last earnings report?
Seres Therapeutics Inc. reported an EPS of -$1.634 in its last earnings report, missing expectations of -$1.477. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Seres Therapeutics Inc.?
Currently, no hedge funds are holding shares in CH:MCRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Seres Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.48%
12-Months-Change
Fundamentals
Return on Equity
-127.30%
Trailing 12-Months
Asset Growth
-28.36%
Trailing 12-Months
Company Description
Seres Therapeutics Inc.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
MCRB Stock 12 Month Forecast
Average Price Target
$17.48
Anixa Biosciences
―
Surrozen
―
Cognition Therapeutics
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Options Prices
Currently, No data available
---